Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Analysts are estimating that Progressive will report an earnings per share (EPS) of $4.29. Investors in Progressive are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Tuesday: JPMorgan Chase, Wells Fargo, Citigroup, BlackRock, and Bank of New York Mellon release results. Wednesday: Bank of ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer PFE is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and Paxlovid.